Lion Biotechnologies, Inc.
|Company Name||Lion Biotechnologies, Inc.|
The Firm announces an investigation on behalf of Lion Biotechnologies, Inc. (“Lion” or the “Company”) (NASDAQ: LBIO) concerning the Company and its officers’ possible violations of federal securities laws.
On April 10, 2017, the U.S. Securities and Exchange Commission found that between “September 2013 to March 2014, Lion, through its former Chief Executive Officer, Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when, in fact, they were paid promotions.” On this news, the price of Lion shares declined, thereby injuring investors.
If you purchased Lion securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224 or by email to email@example.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
Submit Your Information
If you suffered a loss on your Lion Biotechnologies, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.